tert-butyl (3S)-3-(3-aminophenoxy)pyrrolidine-1-carboxylate | 741290-82-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: tert-butyl (3S)-3-(3-aminophenoxy)pyrrolidine-1-carboxylate
• 英文别名: (S)-tert-butyl 3-(3-aminophenoxy)pyrrolidine-1-carboxylate
• CAS: 741290-82-4
• 化学式: C₁₅H₂₂N₂O₃
• 分子量: 278.351
• InChiKey: OEXDUKMNDLZYLG-ZDUSSCGKSA-N

物化性质

• 沸点：
  419.9±35.0 °C(Predicted)
• 密度：
  1.165±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  64.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl (3S)-3-(3-aminophenoxy)pyrrolidine-1-carboxylate 在 盐酸 作用下， 以 1,4-二氧六环 、 甲醇 、 乙酸乙酯 为溶剂， 反应 16.0h， 生成 1,3-dimethyl-4-[3-[(3S)-pyrrolidin-3-yl]oxyanilino]pyrazolo[3,4-b]pyridine-5-carboxamide
  参考文献：
  名称：

  New orally active PDE4 inhibitors with therapeutic potential

  摘要：

  The design synthesis, and biological evaluation of a series of pyrazolopyridines was carried out. Structural optimization of the aniline moiety of 4-anilinopyrazolopyridinc derivative 3a, which is one of the newly discovered chemical leads for PDE4 inhibitors from our in-house library, was performed successfully. The details of the discovery of new orally active PDE4 inhibitors, which are expected to show therapeutic potential, are presented and their structure-activity relationships are discussed. Pharmacological evaluation and pharmacokinetic data for representative compounds are also presented. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.05.032
• 作为产物：
  描述：

  间硝基苯酚 在 palladium on activated charcoal 氢气 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 3.0h， 生成 tert-butyl (3S)-3-(3-aminophenoxy)pyrrolidine-1-carboxylate
  参考文献：
  名称：

  New orally active PDE4 inhibitors with therapeutic potential

  摘要：

  The design synthesis, and biological evaluation of a series of pyrazolopyridines was carried out. Structural optimization of the aniline moiety of 4-anilinopyrazolopyridinc derivative 3a, which is one of the newly discovered chemical leads for PDE4 inhibitors from our in-house library, was performed successfully. The details of the discovery of new orally active PDE4 inhibitors, which are expected to show therapeutic potential, are presented and their structure-activity relationships are discussed. Pharmacological evaluation and pharmacokinetic data for representative compounds are also presented. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.05.032

文献信息

• Imidazopyrazines as protein kinase inhibitors
  申请人：Zhao Lianyun

  公开号：US20070117804A1

  公开（公告）日：2007-05-24

  In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions.

  本发明的多种实施例提供了一类新型的咪唑吡嗪化合物，作为蛋白质和/或检查点激酶的抑制剂，包括制备这类化合物的方法、包含一个或多个这类化合物的药物组合物、制备包含一个或多个这类化合物的药物制剂的方法，以及使用这类化合物或药物组合物治疗、预防、抑制或改善与蛋白质或检查点激酶相关的一个或多个疾病的方法。
• 嘧啶衍生物及其制备方法和在医药上的应用
  申请人：四川海思科制药有限公司

  公开号：CN105384695B

  公开（公告）日：2019-12-20

  本发明涉及一种嘧啶衍生物及其制备方法和在医药上的应用，具体而言本发明涉及通式(M)所示的化合物或者其立体异构体、水合物、代谢产物、溶剂化物、药学上可接受的盐、共晶或者前药、它们的制备方法、包括其药物组合物以及本发明的化合物药物组合物在医药上的用途，特别作为EGFR靶点抑制剂的用途，其中，通式(M)中各取代基的定义与说明书的定义相同。
• Methods for inhibiting protein kinases
  申请人：Guzi J. Timothy

  公开号：US20070105864A1

  公开（公告）日：2007-05-10

  The present invention provides methods for inhibiting protein kinases selected from the group consisting of AKT, Checkpoint kinase, Aurora kinase, Pim-1 kinase, and tyrosine kinase using imidazo[1,2-a]pyrazine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with protein kinases using such compounds.

  本发明提供了利用咪唑并[1,2-a]吡嗪化合物抑制来自AKT、检查点激酶、枢纽激酶、Pim-1激酶和酪氨酸激酶的蛋白激酶的方法，以及利用这些化合物治疗、预防、抑制或改善与蛋白激酶相关的一种或多种疾病的方法。
• SUBSTITUTED PYRROLIDINE COMPOUND AND USE THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20200392149A1

  公开（公告）日：2020-12-17

  The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

  本发明提供一种具有促进俄雷欣2型受体激动剂活性的取代吡咯烷化合物。 公式（I）表示的化合物：其中每个符号如说明书中所述，或其盐，具有俄雷欣2型受体激动剂活性，并且可用作预防或治疗嗜睡症的药剂。
• Novel imidazopyrazines as cyclin dependent kinase inhibitors
  申请人：Guzi J. Timothy

  公开号：US20060106023A1

  公开（公告）日：2006-05-18

  In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyrazine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

  在其多种实施方式中，本发明提供了一种新型的咪唑[1,2-a]吡嗪化合物作为细胞周期蛋白依赖性激酶的抑制剂，制备这种化合物的方法，含有一种或多种这样的化合物的制药组合物，制备包含一种或多种这样的化合物的制药配方的方法，以及使用这种化合物或制药组合物治疗、预防、抑制或改善与CDKs相关的一种或多种疾病的方法。